ublituximab   Click here for help

GtoPdb Ligand ID: 8920

Synonyms: Briumvi® | LFB-R603 | TG-1101 | TGTX-1101 | ublituximab-xiiy
Approved drug Immunopharmacology Ligand
ublituximab is an approved drug (FDA (2022), EMA (2023))
Compound class: Antibody
Comment: Ublituximab is a novel third-generation anti-CD20 monoclonal antibody, CD20 being the B lymphocyte cell surface glycoprotein encoded by the MS4A1 gene. This chimeric antibody has been glycoengineered (namely, having a low fucose content in its Fc region) to optimise FcγRIIIA (CD16a) binding, to enhance antibody-dependent cell-mediated cytotoxicity [1-2]. It is being investigated for its immunomodulatory potential.
Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record.
Ublituximab shows similar specificity and a similar glycosylation pattern to the anti-CD20 mAb EMAB-6 [1].
Classification Click here for help
Compound class Antibody
Approved drug? Yes (FDA (2022), EMA (2023))
International Nonproprietary Names Click here for help
INN number INN
9334 ublituximab
Synonyms Click here for help
Briumvi® | LFB-R603 | TG-1101 | TGTX-1101 | ublituximab-xiiy
Database Links Click here for help
Specialist databases
IMGT/mAb-DB 372
Other databases
GtoPdb PubChem SID 310264701
Search PubMed clinical trials ublituximab
Search PubMed titles ublituximab
Search PubMed titles/abstracts ublituximab